APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Dermatomyositis Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Dermatomyositis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173983580319 December 2025194 pages

Choose your research edition.

Industry ResearchDermatomyositis Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Dermatomyositis Drug Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Dermatomyositis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dermatomyositis Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Dermatomyositis Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Dermatomyositis Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Dermatomyositis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Dermatomyositis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dermatomyositis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Dermatomyositis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Dermatomyositis Drug include Novartis AG, Eli Lilly and Company, Pfizer Inc, Octapharma AG, Neovacs SA, MedImmune LLC, Marathon Pharmaceuticals LLC, KPI Therapeutics Inc and Idera Pharmaceuticals Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Dermatomyositis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Dermatomyositis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Dermatomyositis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Dermatomyositis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Dermatomyositis Drug Segment by Company

Novartis AG

Eli Lilly and Company

Pfizer Inc

Octapharma AG

Neovacs SA

MedImmune LLC

Marathon Pharmaceuticals LLC

KPI Therapeutics Inc

Idera Pharmaceuticals Inc

Hope Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Dermatomyositis Drug Segment by Type

Immune Globulin

Dalazatide

Baricitinib

Abatacept

IMO-8400

Others

Dermatomyositis Drug Segment by Application

Hospital

Clinic

Others

Dermatomyositis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dermatomyositis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dermatomyositis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dermatomyositis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Dermatomyositis Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Dermatomyositis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Dermatomyositis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Dermatomyositis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Dermatomyositis Drug Industry Trends Table 2. Dermatomyositis Drug Industry Drivers Table 3. Dermatomyositis Drug Industry Opportunities and Challenges Table 4. Dermatomyositis Drug Industry Restraints Table 5. Global Dermatomyositis Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Dermatomyositis Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Dermatomyositis Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Dermatomyositis Drug Sales Market Share by Manufacturers Table 9. Global Dermatomyositis Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Dermatomyositis Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Dermatomyositis Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Dermatomyositis Drug Manufacturers, Product Type & Application Table 13. Global Dermatomyositis Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Dermatomyositis Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Immune Globulin Table 17. Major Manufacturers of Dalazatide Table 18. Major Manufacturers of Baricitinib Table 19. Major Manufacturers of Abatacept Table 20. Major Manufacturers of IMO-8400 Table 21. Major Manufacturers of Others Table 22. Global Dermatomyositis Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Dermatomyositis Drug Sales by Type (2021-2026) & (K Units) Table 24. Global Dermatomyositis Drug Sales by Type (2027-2032) & (K Units) Table 25. Global Dermatomyositis Drug Sales Market Share by Type (2021-2026) Table 26. Global Dermatomyositis Drug Sales Market Share by Type (2027-2032) Table 27. Global Dermatomyositis Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Dermatomyositis Drug Revenue by Type (2021-2026) & (K Units) Table 29. Global Dermatomyositis Drug Revenue by Type (2027-2032) & (K Units) Table 30. Global Dermatomyositis Drug Revenue Market Share by Type (2021-2026) Table 31. Global Dermatomyositis Drug Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Hospital Table 33. Major Manufacturers of Clinic Table 34. Major Manufacturers of Others Table 35. Global Dermatomyositis Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Dermatomyositis Drug Sales by Application (2021-2026) & (K Units) Table 37. Global Dermatomyositis Drug Sales by Application (2027-2032) & (K Units) Table 38. Global Dermatomyositis Drug Sales Market Share by Application (2021-2026) Table 39. Global Dermatomyositis Drug Sales Market Share by Application (2027-2032) Table 40. Global Dermatomyositis Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Dermatomyositis Drug Revenue by Application (2021-2026) & (K Units) Table 42. Global Dermatomyositis Drug Revenue by Application (2027-2032) & (K Units) Table 43. Global Dermatomyositis Drug Revenue Market Share by Application (2021-2026) Table 44. Global Dermatomyositis Drug Revenue Market Share by Application (2027-2032) Table 45. Global Dermatomyositis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Dermatomyositis Drug Sales by Region (2021-2026) & (K Units) Table 47. Global Dermatomyositis Drug Sales Market Share by Region (2021-2026) Table 48. Global Dermatomyositis Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global Dermatomyositis Drug Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Dermatomyositis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America Dermatomyositis Drug Sales by Country (2021-2026) & (K Units) Table 52. North America Dermatomyositis Drug Sales by Country (2027-2032) & (K Units) Table 53. Europe Dermatomyositis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe Dermatomyositis Drug Sales by Country (2021-2026) & (K Units) Table 55. Europe Dermatomyositis Drug Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific Dermatomyositis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific Dermatomyositis Drug Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific Dermatomyositis Drug Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa Dermatomyositis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa Dermatomyositis Drug Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa Dermatomyositis Drug Sales by Country (2027-2032) & (K Units) Table 62. Global Dermatomyositis Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Dermatomyositis Drug Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Dermatomyositis Drug Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Dermatomyositis Drug Revenue Market Share by Region (2021-2026) Table 66. Global Dermatomyositis Drug Revenue Market Share by Region (2027-2032) Table 67. Novartis AG Company Information Table 68. Novartis AG Business Overview Table 69. Novartis AG Dermatomyositis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Novartis AG Dermatomyositis Drug Product Portfolio Table 71. Novartis AG Recent Development Table 72. Eli Lilly and Company Company Information Table 73. Eli Lilly and Company Business Overview Table 74. Eli Lilly and Company Dermatomyositis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Eli Lilly and Company Dermatomyositis Drug Product Portfolio Table 76. Eli Lilly and Company Recent Development Table 77. Pfizer Inc Company Information Table 78. Pfizer Inc Business Overview Table 79. Pfizer Inc Dermatomyositis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Pfizer Inc Dermatomyositis Drug Product Portfolio Table 81. Pfizer Inc Recent Development Table 82. Octapharma AG Company Information Table 83. Octapharma AG Business Overview Table 84. Octapharma AG Dermatomyositis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Octapharma AG Dermatomyositis Drug Product Portfolio Table 86. Octapharma AG Recent Development Table 87. Neovacs SA Company Information Table 88. Neovacs SA Business Overview Table 89. Neovacs SA Dermatomyositis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Neovacs SA Dermatomyositis Drug Product Portfolio Table 91. Neovacs SA Recent Development Table 92. MedImmune LLC Company Information Table 93. MedImmune LLC Business Overview Table 94. MedImmune LLC Dermatomyositis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. MedImmune LLC Dermatomyositis Drug Product Portfolio Table 96. MedImmune LLC Recent Development Table 97. Marathon Pharmaceuticals LLC Company Information Table 98. Marathon Pharmaceuticals LLC Business Overview Table 99. Marathon Pharmaceuticals LLC Dermatomyositis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Marathon Pharmaceuticals LLC Dermatomyositis Drug Product Portfolio Table 101. Marathon Pharmaceuticals LLC Recent Development Table 102. KPI Therapeutics Inc Company Information Table 103. KPI Therapeutics Inc Business Overview Table 104. KPI Therapeutics Inc Dermatomyositis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. KPI Therapeutics Inc Dermatomyositis Drug Product Portfolio Table 106. KPI Therapeutics Inc Recent Development Table 107. Idera Pharmaceuticals Inc Company Information Table 108. Idera Pharmaceuticals Inc Business Overview Table 109. Idera Pharmaceuticals Inc Dermatomyositis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Idera Pharmaceuticals Inc Dermatomyositis Drug Product Portfolio Table 111. Idera Pharmaceuticals Inc Recent Development Table 112. Hope Pharmaceuticals Inc Company Information Table 113. Hope Pharmaceuticals Inc Business Overview Table 114. Hope Pharmaceuticals Inc Dermatomyositis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Hope Pharmaceuticals Inc Dermatomyositis Drug Product Portfolio Table 116. Hope Pharmaceuticals Inc Recent Development Table 117. F. Hoffmann-La Roche Ltd Company Information Table 118. F. Hoffmann-La Roche Ltd Business Overview Table 119. F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. F. Hoffmann-La Roche Ltd Dermatomyositis Drug Product Portfolio Table 121. F. Hoffmann-La Roche Ltd Recent Development Table 122. Key Raw Materials Table 123. Raw Materials Key Suppliers Table 124. Dermatomyositis Drug Distributors List Table 125. Dermatomyositis Drug Customers List Table 126. Research Programs/Design for This Report Table 127. Authors List of This Report Table 128. Secondary Sources Table 129. Primary Sources List of Figures Figure 1. Dermatomyositis Drug Product Image Figure 2. Global Dermatomyositis Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dermatomyositis Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Dermatomyositis Drug Sales (2021-2032) & (K Units) Figure 5. Global Dermatomyositis Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Dermatomyositis Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Immune Globulin Image Figure 9. Dalazatide Image Figure 10. Baricitinib Image Figure 11. Abatacept Image Figure 12. IMO-8400 Image Figure 13. Others Image Figure 14. Global Dermatomyositis Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Dermatomyositis Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Dermatomyositis Drug Sales Market Share by Type (2021-2032) Figure 17. Global Dermatomyositis Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Dermatomyositis Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Dermatomyositis Drug Revenue Market Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Others Image Figure 23. Global Dermatomyositis Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Dermatomyositis Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Dermatomyositis Drug Sales Market Share by Application (2021-2032) Figure 26. Global Dermatomyositis Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Dermatomyositis Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Dermatomyositis Drug Revenue Market Share by Application (2021-2032) Figure 29. North America Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America Dermatomyositis Drug Sales Market Share by Country (2021-2032) Figure 31. U.S. Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Dermatomyositis Drug Sales Market Share by Country (2021-2032) Figure 36. Germany Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Dermatomyositis Drug Sales Market Share by Country (2021-2032) Figure 43. China Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Dermatomyositis Drug Sales Market Share by Country (2021-2032) Figure 51. Brazil Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile Dermatomyositis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global Dermatomyositis Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Dermatomyositis Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Dermatomyositis Drug Revenue (2021-2032) & (US$ Million) Figure 62. North America Dermatomyositis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Dermatomyositis Drug Revenue (2021-2032) & (US$ Million) Figure 64. Europe Dermatomyositis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Dermatomyositis Drug Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Dermatomyositis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Dermatomyositis Drug Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Dermatomyositis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Dermatomyositis Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Dermatomyositis Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Immune Globulin
  • Dalazatide
  • Baricitinib
  • Abatacept
  • IMO-8400
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Eli Lilly and Company
  • Pfizer Inc
  • Octapharma AG
  • Neovacs SA
  • MedImmune LLC
  • Marathon Pharmaceuticals LLC
  • KPI Therapeutics Inc
  • Idera Pharmaceuticals Inc
  • Hope Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Dermatomyositis Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Dermatomyositis Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Dermatomyositis Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Dermatomyositis Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Dermatomyositis Drug Market Dynamics
  1. 2.1 Dermatomyositis Drug Industry Trends
  2. 2.2 Dermatomyositis Drug Industry Drivers
  3. 2.3 Dermatomyositis Drug Industry Opportunities and Challenges
  4. 2.4 Dermatomyositis Drug Industry Restraints
3 Dermatomyositis Drug Market by Manufacturers
  1. 3.1 Global Dermatomyositis Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Dermatomyositis Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Dermatomyositis Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Dermatomyositis Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Dermatomyositis Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Dermatomyositis Drug Manufacturers, Product Type & Application
  7. 3.7 Global Dermatomyositis Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Dermatomyositis Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Dermatomyositis Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Dermatomyositis Drug Tier 1, Tier 2, and Tier 3
4 Dermatomyositis Drug Market by Type
  1. 4.1 Dermatomyositis Drug Type Introduction
  2. 4.1.1 Immune Globulin
  3. 4.1.2 Dalazatide
  4. 4.1.3 Baricitinib
  5. 4.1.4 Abatacept
  6. 4.1.5 IMO-8400
  7. 4.1.6 Others
  8. 4.2 Global Dermatomyositis Drug Sales by Type
  9. 4.2.1 Global Dermatomyositis Drug Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Dermatomyositis Drug Sales by Type (2021-2032)
  11. 4.2.3 Global Dermatomyositis Drug Sales Market Share by Type (2021-2032)
  12. 4.3 Global Dermatomyositis Drug Revenue by Type
  13. 4.3.1 Global Dermatomyositis Drug Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Dermatomyositis Drug Revenue by Type (2021-2032)
  15. 4.3.3 Global Dermatomyositis Drug Revenue Market Share by Type (2021-2032)
5 Dermatomyositis Drug Market by Application
  1. 5.1 Dermatomyositis Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Dermatomyositis Drug Sales by Application
  6. 5.2.1 Global Dermatomyositis Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Dermatomyositis Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Dermatomyositis Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Dermatomyositis Drug Revenue by Application
  10. 5.3.1 Global Dermatomyositis Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Dermatomyositis Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Dermatomyositis Drug Revenue Market Share by Application (2021-2032)
6 Global Dermatomyositis Drug Sales by Region
  1. 6.1 Global Dermatomyositis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Dermatomyositis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Dermatomyositis Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Dermatomyositis Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Dermatomyositis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Dermatomyositis Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Dermatomyositis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Dermatomyositis Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Dermatomyositis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Dermatomyositis Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Dermatomyositis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Dermatomyositis Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Dermatomyositis Drug Revenue by Region
  1. 7.1 Global Dermatomyositis Drug Revenue by Region
  2. 7.1.1 Global Dermatomyositis Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Dermatomyositis Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Dermatomyositis Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Dermatomyositis Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Dermatomyositis Drug Revenue (2021-2032)
  8. 7.2.2 North America Dermatomyositis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Dermatomyositis Drug Revenue (2021-2032)
  11. 7.3.2 Europe Dermatomyositis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Dermatomyositis Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Dermatomyositis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Dermatomyositis Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Dermatomyositis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Dermatomyositis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Dermatomyositis Drug Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Eli Lilly and Company
  8. 8.2.1 Eli Lilly and Company Company Information
  9. 8.2.2 Eli Lilly and Company Business Overview
  10. 8.2.3 Eli Lilly and Company Dermatomyositis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly and Company Dermatomyositis Drug Product Portfolio
  12. 8.2.5 Eli Lilly and Company Recent Developments
  13. 8.3 Pfizer Inc
  14. 8.3.1 Pfizer Inc Company Information
  15. 8.3.2 Pfizer Inc Business Overview
  16. 8.3.3 Pfizer Inc Dermatomyositis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Inc Dermatomyositis Drug Product Portfolio
  18. 8.3.5 Pfizer Inc Recent Developments
  19. 8.4 Octapharma AG
  20. 8.4.1 Octapharma AG Company Information
  21. 8.4.2 Octapharma AG Business Overview
  22. 8.4.3 Octapharma AG Dermatomyositis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Octapharma AG Dermatomyositis Drug Product Portfolio
  24. 8.4.5 Octapharma AG Recent Developments
  25. 8.5 Neovacs SA
  26. 8.5.1 Neovacs SA Company Information
  27. 8.5.2 Neovacs SA Business Overview
  28. 8.5.3 Neovacs SA Dermatomyositis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Neovacs SA Dermatomyositis Drug Product Portfolio
  30. 8.5.5 Neovacs SA Recent Developments
  31. 8.6 MedImmune LLC
  32. 8.6.1 MedImmune LLC Company Information
  33. 8.6.2 MedImmune LLC Business Overview
  34. 8.6.3 MedImmune LLC Dermatomyositis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 MedImmune LLC Dermatomyositis Drug Product Portfolio
  36. 8.6.5 MedImmune LLC Recent Developments
  37. 8.7 Marathon Pharmaceuticals LLC
  38. 8.7.1 Marathon Pharmaceuticals LLC Company Information
  39. 8.7.2 Marathon Pharmaceuticals LLC Business Overview
  40. 8.7.3 Marathon Pharmaceuticals LLC Dermatomyositis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Marathon Pharmaceuticals LLC Dermatomyositis Drug Product Portfolio
  42. 8.7.5 Marathon Pharmaceuticals LLC Recent Developments
  43. 8.8 KPI Therapeutics Inc
  44. 8.8.1 KPI Therapeutics Inc Company Information
  45. 8.8.2 KPI Therapeutics Inc Business Overview
  46. 8.8.3 KPI Therapeutics Inc Dermatomyositis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 KPI Therapeutics Inc Dermatomyositis Drug Product Portfolio
  48. 8.8.5 KPI Therapeutics Inc Recent Developments
  49. 8.9 Idera Pharmaceuticals Inc
  50. 8.9.1 Idera Pharmaceuticals Inc Company Information
  51. 8.9.2 Idera Pharmaceuticals Inc Business Overview
  52. 8.9.3 Idera Pharmaceuticals Inc Dermatomyositis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Idera Pharmaceuticals Inc Dermatomyositis Drug Product Portfolio
  54. 8.9.5 Idera Pharmaceuticals Inc Recent Developments
  55. 8.10 Hope Pharmaceuticals Inc
  56. 8.10.1 Hope Pharmaceuticals Inc Company Information
  57. 8.10.2 Hope Pharmaceuticals Inc Business Overview
  58. 8.10.3 Hope Pharmaceuticals Inc Dermatomyositis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Hope Pharmaceuticals Inc Dermatomyositis Drug Product Portfolio
  60. 8.10.5 Hope Pharmaceuticals Inc Recent Developments
  61. 8.11 F. Hoffmann-La Roche Ltd
  62. 8.11.1 F. Hoffmann-La Roche Ltd Company Information
  63. 8.11.2 F. Hoffmann-La Roche Ltd Business Overview
  64. 8.11.3 F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 F. Hoffmann-La Roche Ltd Dermatomyositis Drug Product Portfolio
  66. 8.11.5 F. Hoffmann-La Roche Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Dermatomyositis Drug Value Chain Analysis
  2. 9.1.1 Dermatomyositis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Dermatomyositis Drug Production Mode & Process
  6. 9.2 Dermatomyositis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Dermatomyositis Drug Distributors
  9. 9.2.3 Dermatomyositis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst